Hemab Therapeutics Holdings, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| COAG | IRON | QURE | DMRA | ADMA | AGMB | |
|---|---|---|---|---|---|---|
| Market cap | 1.42B | 2.32B | 1.51B | 1.25B | 2.28B | 447.66M |
| P/E (TTM) | — | — | — | — | 14.5 | — |
| Forward P/E | -12.0 | -8.5 | -7.2 | -9.3 | 10.8 | -4.4 |
| Price/book | 3.1 | 3.6 | 4.7 | 3.2 | 5.6 | 3.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −7.00% | −13.76% | −63.58% | +65.33% | −31.91% | −37.95% |
| Today | −3.89% | −2.55% | −3.32% | −3.91% | −1.74% | +0.11% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All COAG news ›Hemab Therapeutics (NASDAQ:COAG) Stock Price Down 7.5% - What's Next?
Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) dropped 7.5% during trading on Tuesday. The stock traded as low as $28.12 and last traded at $28.31. 119,924 shares traded hands during mid-day trading, a decline…
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of "Moderate Buy" from Analysts
Get Our Latest Stock Analysis on COAG COAG opened at $30.84 on Thursday. The stock has a market capitalization of $1.44 billion and a PE ratio of -1.24. The company's 50 day simple moving average is $45.06. Hemab Therapeutics has a 52-week…
Hemab Therapeutics (NASDAQ:COAG) Sees Unusually-High Trading Volume - Still a Buy?
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) saw unusually-high trading volume on Wednesday. Approximately 332,235 shares traded hands during mid-day trading, a decline of 11% from the previous session's volume of…
Hemab Therapeutics: The Market Is Pricing One Rung Of A Four-Rung Ladder (NASDAQ:COAG)
Hemab Therapeutics (COAG) investment overview: sutacimig cut bleeds ~84% in GT; Phase 3 in 2H 2026; VWD/HMB upside & key risks.
Hemab Therapeutics Holdings, Inc. Announces Board and Committee Changes, Effective September 24, 2026
Hemab Therapeutics announced the appointment of Keli Walbert to its Board of Directors, effective September 24, 2026. Ms. Walbert will join the Board?s Audit Committee, succeeding Akshay Vaishnaw, MD, ... Hemab Therapeutics announced the…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketbeat.com3
-
manilatimes.net1
-
marketscreener.com1
-
medwatch.com1
-
seekingalpha.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.